AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...

Other AbbVie drugs, including its once-best-selling multiuse medication Humira, have been targeted by new provisions in the ...

Discover how to navigate inflation with long-term investments in resilient companies like Coca-Cola, AbbVie, and TC Energy.

Guggenheim Securities adjusted its financial outlook for shares of AbbVie Inc . (NYSE:ABBV), reducing the price target to $212 from the previous $221, while still recommending a Buy rating for the ...

Humira is a treatment for moderate to severe ... Abbott created the Established Pharmaceuticals Division in 2010. The creation of AbbVie In 2011, Abbott announced it was to separate into two ...

Organon has faced significant price volatility and underperformance since its spin-off from Merck. Check out why I recommend ...

The two deals are part of a concerted effort to bolster AbbVie’s product portfolio and R&D pipeline and help the company cope with the loss of patent protection for immunology behemoth Humira ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on ABBV stock, giving a Buy rating yesterday.Stay Ahead of the ...

Piper Sandler raised the firm’s price target on Teva (TEVA) to $30 from $23 and keeps an Overweight rating on the shares after meeting with ...